Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rexmyelocel T - Ixaka

Next Previous
Drug Profile

Rexmyelocel T - Ixaka

Alternative Names: BM-MNCs - Ixaka; Bone marrow-derived mononuclear cells - Ixaka; REX-001

Latest Information Update: 19 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rexgenero
  • Developer Ixaka
  • Class Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Peripheral ischaemia

Most Recent Events

  • 19 Jan 2025 No development reported - Phase-III for Peripheral ischaemia in Austria, Hungary, Poland, Portugal, Czech Republic, Netherlands, United Kingdom, Germany, Spain (Intra-arterial)
  • 21 May 2021 Rexgenero initiates enrolment in a phase III clinical trials in Peripheral ischaemia in Netherlands and Czech Republic (Intra-arterial) (NCT03111238) (EudraCT2016-000240-34)
  • 31 Mar 2021 Rexgenero terminates a phase III clinical trials in Peripheral ischaemia in Austria, Hungary, Poland, Portugal, Netherlands, Germany, Czech Republic and Spain Republic (Intra-arterial) (NCT03111238)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top